Abstract | In female animals, energy metabolism and fertility are tightly connected, and reciprocally regulated. However, the relative contributions of metabolic and reproductive pathways have changed over the course of evolution. In oviparous animals, metabolic factors take precedence over fertility, enabling egg production to be inhibited in a nutritionally poor environment. By contrast, in placental mammals, the opposite occurs: the need to feed a developing embryo and neonate forces metabolic pathways to adapt to these reproductive needs. This physiological necessity explains why in female mammals alterations of gonadal activity, including age-dependent cessation of ovarian functions, are associated with a disruption of metabolic homeostasis and consequent inflammatory reactions that trigger the onset of metabolic, cardiovascular, skeletal and neural pathologies. This Review discusses how metabolic homeostasis and reproductive functions interact to optimize female fertility and explains the pathogenic mechanisms underlying the disordered energy metabolism associated with human ovarian dysfunction owing to menopause, polycystic ovary syndrome and Turner syndrome. Finally, this article highlights how hormone replacement therapy might aid the restoration of metabolic homeostasis in women with ovarian dysfunction.
Introduction
Although women have a greater life expectancy than men, the gap is narrowing. 1 From 1990 to 2011 the difference in life expectancy between men and women dropped from an average of 6.61 to 4.67 years in European countries and from 7 to 5 years in the USA. 2 The fact that women develop an increased susceptibility to weight gain as they age 3 could potentially contribute to this phenom enon, because obesity is a wellknown risk factor for a large number of metabolic, cardiovascular and skeletal dis orders. 4 Understanding the biological basis of weight gain in ageing women is, therefore, relevant to define ap propriate st rategies to combat obesity in this population.
One interesting hypothesis suggests that the female specifi c propensity to weight gain (and, thereby, to metabolic dysfunction) might be the consequence of adaptations that enable reproduction and nurturing of offspring in foodscarce environments. 3 Uncontrolled reproduction in a nutritionally poor environment would lead to competition for food between mothers and their offspring, which ultimately might result in extinction of the species. Female fertility and energy metabolism are, therefore, tightly interconnected; during the reproduc tive period of life, the physiological activity of the gonads, with their cyclic production of sex hormones, ensures a continuous regulation of food intake and energy expendi ture. However, with the cessation of ovarian function, gonadal control over energy metabolism decreases, with negative consequences. In women, weight gain and obesity are most prevalent around and after menopause. 5 Moreover, pathol ogies that involve ovarian dysfunction, such as polycystic ovary syndrome (PCOS) and Turner syndrome, are generally associated with metabolic dis orders. 6, 7 Thus, an obesogenic milieu might be particu larly metabolically harmful in species adapted to survive in nutrientpoor environments.
The molecular mechanisms involved in the inter actions between fertility and metabolism have been little investi gated in mammals. However, the remarkable similarities in these mechanisms among oviparous species demon strate that strong selection pressure has favoured the preservation of pathways that coordinate reproductive functions with energy availability. Indeed, mechanisms that limit female gonadal activity during times of calorie restriction should have been positively selected for in all species during evolution. 8 An appreciation of the role of evolution in shaping these reproductive and metabolic pathways might, therefore, improve our understanding of human female physiology.
In this Review, we discuss how the reciprocal inter actions between pathways that control fertility and energy metabolism are organized and underline the key roles of molecules such as estrogens and insulinlike growth factors (IGFs) in these pathways. We also discuss how this novel perspective could challenge current therapeu tic strategies-amelioration of metabolic disorders, for example, might become an important goal of hormone replacement therapy (HRT), particularly in ageing women.
Nutritional status-links to fertility

Mechanisms in oviparous species
In oviparous species, the most important yolk proteins are vitellogenins, a family of large glycoproteins that provide nutrients (such as amino acids, carbohydrates, phosphates and sulphates) to the embryo, as well as lipids, hormones, vitamins and metals. 9 Synthesis of vitello genins takes place in metabolic organs that are function ally comparable to liver. 10 Vitellogenins also have a key role in fat storage and mobilization; thus, egg maturation ceases when energy availability is restricted. Moreover, vitellogenins and the molecular pathways directing their synthesis are wellconserved across all oviparous species, from invertebrates to vertebrates. 11 In liverlike tissues, stimuli from local sources and the nervous system (such as insulinlike peptides, 12 amino acids and nutritional signalling factors, such as target of rapamycin 13 ), 12, 14 control vitellogenin production in concert with gonadal hormones (ecdysone and estrogens) to signal the state of egg development and m aturation ( Figure 1 ).
Mechanisms in placental mammals
In mammals, including primates, severe malnutrition and allostatic overload reduce fertility. 15 Reproduction is still arrested in nutritionally unfavourable settings, but the mechanisms involved have increased complexity compar ed with those in oviparous species.
In the mammalian liver, estrogenregulated synthesis of apolipoproteins 16 seems to have a role in maintain ing reproductive capacity, as defective hepatic produc tion of VLDL leads to female sterility. 17 Interestingly,
Key points
■ Metabolic and reproductive pathways are tightly associated, and this relationship has been conserved throughout evolution ■ Reproductive disorders can lead to changes in metabolic function ■ Similarly, metabolic disorders can underlie changes in reproductive function ■ Hormone replacement therapy for reproductive disorders might also have beneficial effects on energy metabolism Figure 1 | The mutual control of nutritional status and reproduction throughout evolution. In oviparous animals, vitellogenin synthesis takes place in the organ functionally comparable to the mammalian liver, 9 and is regulated by nutritional cues together with gonadal hormones (such as ecdysone or estrogens). 13 Once synthesized, these lipid transport proteins are secreted into the circulatory system to reach the gonads where they regulate the maturation of the egg. Vitellogenins and the proteins they transport provide the embryo with energy necessary for its development. In all oviparous animals, therefore, nutritional cues have a direct control over reproduction regulating oogenesis, or inducing infertility or a dormant fertility state (dauer and diapause). In placental mammals, the liver regulates gonadal function through the synthesis of the lipid transport protein apoB (a member of the vitellogenin family) and the synthesis of IGF-1. [144] [145] [146] Estrogens, together with dietary intake, regulate liver production of both apoB and IGF-1. In addition, estrogens have a strong influence on the activity of all organs relevant for energy metabolism and provide the embryo with the energy molecules necessary for its growth. In mammals the control of energy metabolism on reproduction, typical of oviparous animals, is maintained, but reproductive functions become the key driver of metabolic functions. Abbreviations: AA, amino acids; apoB, apolipoprotein B-100; E2, estradiol; GH, growth hormone; IGF, insulin-like growth factor; ILPs, insulin-like peptides; IPC, insulin-producing cells; JH, juvenile hormones; LDLR, LDL receptor; Sperm-dep, sperm dependent; Vg, vitellogenin. 
Gonadotropins
Brockmann body apolipoprotein B100 (apoB100) contains a vitello genin domain, 18 and placenta formation is impaired in apoBknockout mice. 19 Moreover, dietary intakes of amino acids can also regulate fertility. 20 Hepatic syn thesis of IGF1, which is essential for the reproductive cycle, is regulated by aminoaciddependent activation of estrogen receptor (ER) α in the liver. 21 These mecha nisms resemble those in oviparous species. However, in placental animals, the central regulation of energy expenditure and reproduction takes precedence over these ancestral, nutritionbased, mechanisms of fertility control. Peripheral messages converge in the brain nuclei responsible for their integration and for production of the efferent signals that ultimately control allostatic regulation in the organism. Several tissues and organs communicate nutritional status to the cen tral nervous system. White adipose tissue secretes the anorexigenic hormone leptin in amounts proportional to the amount of energy stored as fat. 22 The stomach pro duces the orexigenic hormone ghrelin. 23 The intestine secretes peptide YY in response to food intake, which induces satiety. 24 Finally, the pancreas releases insulin, which has a similar action to leptin in the hypo thalamus. 25 All these signals converge and are integrated in the brain stem and arcuate nucleus which, together with other hypothalamic nuclei, regulate both ovulation and energy homeostasis. For example, sensors of energy status in the arcuate nucleus-such as cocaine and amphetamine regulated transcript (CART)-proopiomelanocorti n (POMC) neurons and agoutirelated peptide (AgRP)-neuropeptide Y (NPY) neurons-direct the synthesis of gonadotropins in the pituitary by regulating the activity of gonadotropinreleasing hormone (GnRH) neurons located in the preoptic area ( Figure 2 ). 26 In placental mammals, the nutritional burden asso ciated with development of the embryo and growth of the offspring has been transferred to the mother. Conse quently, the regulatory mechanisms linking energy avail ability and reproductive function had to be adapted to take into account the variable energy demands of each stage of the reproductive cycle (periodic ovulation, preg nancy and lactation). 26 Thus, the need to have highly reciprocal control of both energy sensing and reproduc tion might have favoured the selection of ERα and ERβ as the nexus through which these two functions are linked. Indeed, these receptors can be activated by nutritional signalling molecules (such as amino acids and IGF1), as well as gonadal hormones, 21 and can regulate expression of a diverse range of genes. 26 ERα and ERβ are exception ally versatile sensory and regulatory effectors that are widely expressed in mammalian tissues. 27 The essential role of estrogens and their receptors in reproduction has long been known. However, emerg ing evidence suggests that estrogen signalling also has a central role in the control of energy metabolism. The concentration of various circulating estrogen metabo lites such as estradiol, estrone, estriol and their ratio depends on fertility status. 28 The exact role of each of these metabolites is unclear; therefore, in this Review, the term estrogens refers to all estrogenic compounds. The major naturally occurring estrogens in women are estrone, estradiol (which has the most potent effect on ERα and ERβ), and estriol (which has the least potency). In addition, pregnant women produce estetrol. Estradiol is the predominant estrogen produced during the repro ductive years (mean levels of which rise from a nadir of 106.5 ± 25.7 pmol/l of plasma during menstruation, to a peak of 1167.4 ± 99.1 pmol/l of plasma around midcycle). Changes in estrone concentrations follow a similar, although less marked, pattern (from a nadir of 148.0 ± 14.8 pmol/l during menstruation, to a peak Estrogens act on SF-1 neurons (purple) in the ventromedial hypothalamus to regulate energy expenditure and fat distribution. ERα in the arcuate nucleus is a critical regulator of food intake, whereas ERα in the ventromedial hypothalamus regulates energy expenditure. 39 Finally, POMC/CART (through kisspeptin and second-order neurons) and SF-1 neurons signal energetic status to GnRH neurons (orange) that are responsible for the pituitary release of gonadotropins, thereby regulating plasma estrogen levels. AgRP/NPY and POMC/ CART neurons express receptors for leptin that allow them to be sensitive to the amount of energy stored in fat. Abbreviations: AgRP, agouti-related protein; CART, cocaine and amphetamine-regulated transcript; DMH, dorsomedial hypothalamus; ERα, estrogen receptor α; GnRH, gonadotrophin releasing hormone; LH, lateral hypothalamus; ME, median eminence; NPY, neuropeptide Y; POA, preoptic area; POMC, pro-opiomelanocortin; PVN, paraventricular nucleus; SF-1, steroidogenic factor-1; VMH, ventromedial hypothalamus.
of 628.8 ± 48.1 pmol/l at midcycle). 29 With menopause, estradiol levels decrease markedly, although estrone levels remain comparable to those observed in fertile women. The transcriptional programme regulated by ERα and ERβ might be modulated in response to changing levels of circulating hormones, which characterize the different stages of female fertility. 26, 30, 31 Accordingly, the set of genes controlled by ERα and ERβ might substantially change in response to different concentrations and ratios of hor mones. Hence, in the same target tissue, the intracellular activity of these receptors might vary at each reproductive stage or during the estrous cycle, leading to an alternate activation of p athways that control energy metabolism. 26 After loss of estrogen production due to ovariectomy 32 or menopause, 33 adipose tissue mass rapidly increases, and its distribution changes. These effects can be reversed by the administration of HRT. 32 The influence of estro gens on energy metabolism is believed to be largely mediated by ERα. Mice lacking ERα have increased body weight and food intake compared with wildtype litter mates, 34 and administration of ERαselective agonists (but not ERβselective agonists) has anorexigenic effects in these mice. 35, 36 Interestingly, mice lacking ERβ have vari able degrees of reduced fertility, show abnormal follicular maturation and very few corpora lutea, 37 whereas mice lacking ERα are infertile and have markedly hypoplastic reproductive organs and tissues, 27 again highlighting the close a ssociation between regulation of energy balance and fertility.
Estrogenmediated metabolic effects occur at multiple levels. In the brainstem, estrogens potentiate or attenuate the effect of various peptides that signal satiety or hunger, respectively (such as cholecystokinin, which is released from the small intestine in response to food inges tion, 38 or ghrelin, 39 production of which is stimulated by fasting). In the arcuate and ventro medial nuclei, estro gens stimulate POMC and steroidogenic factor 1 (SF1) neurons, 40 thereby repressing the synthesis of orexi genic neuropeptides (such as AgRP and NPY). 41 POMC expression is regulated by ERα; in mice lacking this receptor, leptin and insulin no longer increase POMC expression. 42 Moreover, mice lacking ERα specifically in POMC neurons are hyperphagic and have reduced sensi tivity to leptin, despite POMC expression being main tained in the hypothalamus. 40 Thus, the anorexigenic effect of estrogens on POMC neurons is clearly medi ated by ERα, although whether the underlying mecha nism involves direct regulation of POMC expression or potentiated effects of other anorexi genic hormones, such as leptin, or both remains unclear. POMC neurons also express CART, and, to our knowledge, no data describe whether ERα or ERβ (or both) are involved in CART regulation, even if CART expression is modulated by estradiol. 43 AgRP and NPY are essential targets for the anorexigenic effect of estrogens. AgRP-NPY neurons do not express ERα in vivo. 41 However, given that ERα is abundantly expressed in the arcuate nucleus of the hypo thalamus, 44 whereas expression of ERβ is barely detect able at this location, estrogens might conceivably regulate AgRP-NPY neurons through ERα on other neuronal subtypes (such as kisspeptin neurons in the ventrome dial hypothalamus that innervate AgRP-NPY neurons). The mechanisms through which estrogens regulate GnRH neurons to control fertility are unclear. Estrogen decreases GnRH expression in GT17 cells (a hypotha lamic cell line that expresses ERα and ERβ), an effect that might be mediated by ERα. 45 Although GnRH neurons seem to express only ERβ in vivo, 46 a role for both ERα and ERβ receptors in regulating GnRH neuronal activity as well as GnRH secretion remains probable. Different mechanisms are potentially required, including direct actions of estrogen through ERβexpressing GnRH neurons, and indirect actions of estrogen through ERαexpressing afferents of GnRH neurons.
Moreover, estrogen signalling potentiates leptin sensi tivity, possibly by increasing expression of the leptin receptor in the hypothalamus. 47 The overall effects of increased estrogen signalling are induction of an anorexi genic response and fat redistribution to subcuta neous rather than visceral depots. In the arcuate nucleus, anteroventricular periventricular nucleus and preoptic area, estrogen signalling integrates with afferent signals from peripheral organs and tissues, such as the stomach, pancreas and adipose tissue and, through kisspeptin neurons, controls the release of GnRH 48 in response to an individual's metabolic status. These effects are medi ated mainly by ERα, which is abundantly expressed in these hypothalamic nuclei (Figure 2 ). 49 ERα and ERβ are expressed and active in all metabolic organs. In adipose tissue, estrogens increase subcutane ous fat deposition in lower body areas and decrease lipo lytic activity (which maintains fat stores in case periods of food scarcity occur during pregnancy or lactation). When estrogen signalling decreases, the subcutaneous fat redistributes to visceral areas; 31, 34, 50 this phenomenon has been observed in women after natural or o ophorectomy induced menopause; 32, 33 in animal models of selective ablation of ERα; 27, 34 in humans with lossoffunction ERα polymorphisms; 51 and in ovariectomized mice, the phenotype of which can be partially rescued by treat ment with 17βestradiol. 32 Studies in cultured adipocytes show that estrogens have a direct antilipogenic and pro lipolytic activity in vitro, associated with inducing the expression of hormone sensitive lipases and decreasing the activity of lipoprotein lipase. 52, 53 These same effects of estrogens in fatty acid metabolism are observed in animal models. [52] [53] [54] However, the exact contributions of ERα and ERβ to these activities remain to be defined. Although the results of studies in mice genetically engi neered to lack ERα suggest that ERα is the main receptor involved in the control of adipose tissue distribution, 34 other studies, mainly in cultured adipocytes, suggest that estradiol also has antilipogenic and antiadipogenic effects mediated by ERβ. 55 ERα involvement in the control of lipid metabolism is certainly relevant in the liver, 26 where this receptor isoform is predominant. 27 In addition to controlling the synthesis of lipid transport proteins, such as VLDL, hepatic ERα signalling also regulates the expression of numerous genes, the products of which are involved in pathways of cholesterol and fatty acids synthesis, according to the phase of the menstrual cycle and fertil ity status. 26 The oscillation of lipid biosynthesis induced during the menstrual cycle by fluctuating estrogen levels is necessary to maintain healthy fat metabolism. Menopause, ovariectomy and suppression of ERα activ ity in the liver are all associated with increased hepatic fat deposition. 26 These observations suggest that the changes in estrogen metabolism that accompany each stage of reproductive activity in women might regulate ERα transcriptional activity in the liver, thereby promot ing the release or the storage of energy in the form of fat, as necessary for reproductive function. 26 ERα and ERβ are expressed in all tissues relevant to glucose metabolism, including skeletal muscle and liver. 27 However, the most studied extragonadal site of estro gen action is the pancreas, where its important protec tive effect has been known for decades. 56 In pancreatic β cells, estrogens have an antiapoptotic action, 57 repress both lipid biosynthesis and the accumulation of fat, preventing lipotoxicity, 58 and directly stimulate insulin biosynthesis. 59 This last effect might be important in late pregnancy, when high estrogen levels could synergize with high prolactin levels to promote βcell insulin pro duction, to meet the increased metabolic demand. 60 Of particular relevance with regard to the potential thera peutic use of hormonal interventions is that the beneficial effects of estrogens on pancreatic β cells are observed with physiological plasma estrogen levels, as estrogen con centrations above or below the physiological range are associated with metabolic dysfunction. 61 Animal studies have shown that after ovariectomy, sensitivity to insulin is progressively impaired. The a dministration of estradiol to reach early gestational concentrations of the hormone (734-918 pmol/l) improves insulin sensitivity whereas a 100fold higher physiological dose than normal cycle concentration decreases insulin sensi tivity. 62 Randomized controlled clinical trials should be carried out to better evaluate the longterm effects of oral contraceptives or HRT in women. The use of contra ceptives can de teriorate glucose tolerance; 63 however, low estrogen doses (for example 0.625 mg/day), when administered orally can improve tolerance. 64 Moreover, the Heart Estrogen Progestin replacement study 65 and the Women's Health Initiative found a lower incidence of diabetes mellitus in women taking HRT. 66 Finally, high estrogen levels during late pregnancy (1,278-7,192 pg/ml) 67 decrease insulin sensitivity, which might lead to gestational diabetes mel litus. However, the mechanism mediating these effects requires clarification. Normalization of glycaemia must also take into consideration hormonal status, because sex hormones counteract the effects of insulin. 68 
Metabolic effect of reproductive status
Menopause Given that mammalian reproductive functions also regu late energy homeostasis, the fact that cessation of ovarian function leads to the manifestation of metabolic dis orders is not surprising. Indeed, postmenopausal women have increased vulnerability to a large number of patholo gies, including disorders of the cardiovascular, skeletal, immune and nervous systems. 69 How menopause triggers the onset of such diverse pathologies is unclear; perhaps declining levels of circulating estrogens weaken ERα and ERβ activity and thereby cause subtle alterations of energy metabolism in multiple tissues. Over time, such changes could lead to overt pathology owing to the diversity of organs involved. However, in our opinion, for each indivi dual woman, the risk of developing a specific disease is influenced by genetic and environmental factors, as well as her overall health status ( Figure 3 ).
Altered lipid metabolism
Menopause is associated with increased body weight, decreased lean mass 70 and abdominal fat accumula tion. 33, 71 Several enzymes involved in fat turnover are reduced in adipose tissue from postmenopausal women (such as acetylcoenzyme A carboxylase 1, longchain acyl coenzyme A dehydrogenase and hormonesensitive lipase). 72 Increased insulin resistance is also evident, pos sibly prompted by nonphysiological fatty acid deposits, 73 high levels of circulating free fatty acids, and increased production of reactive oxygen species from mitochon drial βoxidation of fatty acids. 74 Macrophages are recruited by the increased fat mass 75 and, in combination with adipocytes, secrete proinflammatory cytokines and chemokines. [76] [77] [78] Fatty acids also accumulate in the liver, where they facilitate the development of diffuse hepatic steatosis, characteristic of postmenopausal women. 79 This steatosis further contributes to the proinflamma tory state, which facilitates the onset of the pathologies associated with climaterium such as atherosclerosis, osteoporosis and metabolic dysfunctions. Furthermore, in the liver, cessation of estrogenic control of choles terol, fatty acid 26 and lipoprotein metabolism leads to a decrease in production of HDL2 (large, anti atherogenic lipid particles) 80 and an increase of HDL3 (small, proatherogenic particles). 79, 80 Total cholesterol, LDL, tri glycerides, 81 ,82 apoB100 and apoB100containing lipo proteins and lipoprotein(a), 83 a complex of an LDLlike particle and apoA, 81 are also increased, which contribute to the develop ment of an athero genic lipid profile and an increased risk of cardiovascular disease. The loss of estro gen's anti inflammatory action in circulating monocytes and microglia 84, 85 is another important patho physiological element that, together with the altered lipid transport associated with reduced levels of apoE, might lead to brain neurodegenera tive pathologies. For example, the inci dence of disorders such as Alzheimer disease is similarly low in both female and male individuals ≤50 years old, but increases after this age and thereafter is considerably higher in women. 86 
Impaired muscle and bone physiology
After menopause, skeletal muscle function is reduced, as is muscle strength and mass, an effect that is reversed by HRT. 87 Additionally, the decline in expression of the glucose transporter GLUT4, 88 which is associated with impaired muscle ERα activity, together with a general ized proinflammatory milieu might participate in the increased risk of insulin resistance typical in postmeno pausal women. The proinflammatory state and increased levels of circulating cytokines (IL1, IL6 and TNF) also have repercussions in other organs, such as bone, where they contribute to a decrease in BMD and increase in osteoclast number. 89 Nonalcoholic fatty liver disease Nonalcoholic fatty liver disease (NAFLD) is a metabolic condition that leads to liver damage. The spectrum of NAFLD ranges from simple steatosis, through non alcoholic steatohepatitis and cirrhosis, to liver failure and hepatocellular carcinoma. NAFLD is characterized by hepatic lipid accumulation (fat comprises 5-10% of the total organ weight), which is associated with insulin resistance in the liver, 90 increased lipogenesis 90 and reduced secretion of triglycerides. 91 Insufficient suppres sion of lipolysis in adipocytes 72 further contributes to the formation of lipid deposits in the liver. These alterations result in impaired mitochondrial fatty acid oxidation 92 and upregulation of both peroxisomal βoxidation and microsomal ωoxidation. Together with production of lipotoxic lipid intermediates, increased production of ROS, and induction of a proinflammatory response, these changes further contribute to progression of NAFLD and insulin resistance. 93 NAFLD can occur in individuals of all ages and ethnic groups, and has a prevalence of about 30%; 94 this disorder is more common in men, in whom it has a 2.0-3.5fold higher prevalence than in women. 95, 96 After menopause, the incidence of NAFLD increases significantly to reach the levels seen in men. 97 HRT reduces the risk of hepatic steatosis 98 and the prevalence of NAFLD 79 in this population. These and other data, including the associa tion of NAFLD with altered ovarian function, 99 suggest that estrogens protect against the development of NAFLD.
The exact aetiology of NAFLD in postmenopausal women is unclear. However, estrogen deficiency cer tainly contributes to the loss of inhibition of de novo fatty acid synthesis, 26, 100 decreased VLDLmediated export of lipids, 97, 101 and reduced fatty acid oxidation 97, 100 in the liver. This view is supported by studies in ovari ectomized rodents, in which administration of estrogens prevented hepatic fat accumulation by inhibiting expression of genes that encode proteins involved in lipo genesis, including sterol regulatory elementbinding protein 1c, peroxisome proliferatoractivated receptor (PPAR) γ, stearoylcoenzyme A desaturase 1, acetylcoenzyme A carboxylase and fatty acid synthase. 26, 100 Estrogens also facilitate VLDLmediated export of lipids from the liver, by increasing hepatic VLDLtriglyceride produc tion and expression of microsomal triglyceride transfer protein. 97, 101 Finally, estrogens sustain the βoxidation of fatty acids by inducing expression of PPARα.
100
Polycystic ovary syndrome NAFLD is often associated with PCOS, 102 which affects up to 10% of women of reproductive age. 103 PCOS is a major metabolic and reproductive disorder characterized by hyperandrogenism, chronic anovulation and poly cystic ovaries, 104 as well as metabolic disturbances-50% of women with PCOS have overweight or obesity, 105 and dyslipidaemia (increased levels of LDL and decreased levels of HDL) is also commonly observed. 106 In the USA, 39% of women with PCOS have hepatic steatosis, 102 and 50% have insulin resistance and metabolic syndrome. 6 Indeed, insulin resistance, independent of obesity, is the metabolic disorder that is most strongly correlated with PCOS. 107 This decreased insulin signalling might be due to serine hyperphosphorylation of the insulin receptor and its substrate IRS1. 108 The cause of anovulation in women with PCOS has not been clearly identified, but might involve an increase in GnRH pulse frequency, possibly caused by low pro gesterone levels in these patients, which augment both luteinizing hormone release from the pituitary and ovarian androgen production. 109 Insulin might increase luteinizing hormone production and synergize with it to stimulate androgen synthesis by ovarian theca cells, thereby further impairing the development of ovarian follicles. 110, 107 This observation further emphasizes the tight interconnection between metabolic and reproduc tive disturbances in patients with PCOS. The presence of metabolic disorders worsens the clinical and biochemical manifestations of PCOS. Being overweight contributes to hyperandrogenism, insulin resistance and dyslipidae mia; 105, 110 conversely, a reduction in excess body weight ameliorates these abnormal metabolic and reproductive features of PCOS. 105 The oral contraceptive pill has been the mainstay of therapy for women with PCOS for several yearscombinations of estrogens and progestins ameliorate hir sutism, acne and oligomenorrhoea in these patients. 110 ,111
REVIEWS
Additionally, HRT, possibly by reducing abdominal fat deposits, is thought to counteract the worsening of hyperinsulinaemia that occurs with ageing in women with PCOS. 112 Concerns about the use of oral contracep tive therapy in patients with PCOS have been raised by the observation of increased triglyceride and cholesterol levels, 113 a phenomenon that is not in line with either observations from experimental studies of HRT or with the notion that endogenous estrogens protect against dyslipidaemia. 81 Further studies should be carried out to clarify the extent to which these alterations in patients' lipid profiles were related to the specific compound used (ethinyl estradiol), its dosage and route of administration.
Metformin, an antidiabetic agent, can effectively restore ovarian function in women with metabolic disordersindeed, metformin not only reduces insulin levels but also directly stimulates ovarian steroido genesis. 114 However, the effects of this therapy on reproductive outcomes seem to be limited, as live birth rates do not improve in metformintreated women with PCOS (despite improved clinical pregnancy rates). 115 Metformin in combination with oral contraceptives can also mitigate the reproduc tive and metabolic symptoms of PCOS. 111 This obser vation, which is in line with the theory that gonadal hormones are essential for a wellbalanced metabolism, also requires confirmation in additional studies including a statistically relevant number of patients with PCOS.
111
Turner syndrome Turner syndrome is a common genetic disorder affecting 1 in 2,500 liveborn girls 116 that is caused by the total or partial absence of one X chromosome (genotype 45,XO). The most common features of Turner syndrome are infer tility due to gonadal dysgenesis, short stature, 117 metabolic disorders, webbed neck and other physical abnormali ties. 118 Reduced dosage of genes on the X chromosome, which in 46,XX female individuals escape Xinactivation (and are, therefore, functionally diploid), is thought to cause most Turner syndrome features. 119 However, candi date Xchromosome genes responsible for specific Turner syndrome features are yet to be identified. 120 The clinical features of patients with Turner syndrome include obesity, 121 low lean body mass and increased BMI, waist circumference 122 and visceral adipose tissue; 99 more over, triglycerides and LDL levels are elevated, but HDL levels are decreased. 123 Patients with Turner syndrome also have smaller lipid particle sizes than do 46,XX indivi duals. 123 Interestingly, the extent of the differences in lipid levels and particle sizes between 46,XX and 45,XO indivi duals is very similar to that between men and women. 81 Thus, haploinsufficiency of Xchromosome genes whose products are involved in lipid metabolism is probably the cause of dyspilidaemia in patients with Turner syndrome, in agreement with the fact that men generally have a more atherogenic lipid profile than do women. 124 As a result, patients with Turner syndrome have a sevenfold increased risk of mortality from ischaemi c heart disease. 121 Moreover, 80% of patients with Turner syndrome have abnormal liver function, 125 which is associated with intra cellular hepatic lipid accumulation, 99 ,125 elevated levels of liver enzymes, 126 and increased incidence of NAFLD, 99 cirrhosis, 122 liver hyperplasia and inflammation. 127 The hepatic abnormalities seem to be caused by the lack of estradiol production, as estradiol treatment ameliorates these abnormalities. 128 Although many clinical features in patients with Turner syndrome recapitulate the metabolic syndrome, paradoxically, such patients have decreased levels of fasting glucose, insulin and leptin (despite their high vis ceral adiposity), even compared with women who have premature ovarian failure. 129 However, the low insulin levels are thought to result from defective βcell secre tory function 130 or a glucosestorage defect, 131 and the decreased leptin levels are probably attributable to low fasting insulin levels. 132 Impaired glucose homeostasis is also frequent 121, 122 and results in an increased risk of dia betes mellitus, 122, 126 which is the cause of death in 25% of patients with Turner syndrome. 133 Current guidelines for the treatment of Turner syn drome recommend growth hormone therapy and suggest the initiation of estrogenbased HRT in patients aged 12-14 years. 134 Patients with Turner syndrome require high doses of growth hormone to achieve optimal develop ment because they are resistant to its metabolic effects. 7, 135 Growth hormone therapy aids the decrease of adiposity and abdominal fat, and increases lean mass and circulating IGF1 levels, 7 whereas HRT is necessary for female sexual development, normalization of BMD and improvement of neurocognitive functions. 118 Furthermore, estrogen therapy has important beneficial effects on the metabolic derangements associated with Turner syndrome, resulting from decreasing visceral adipose tissue, 7 increasing HDL levels 121 and maintaining normal liver metabolism. 128 Indeed, estradiol therapy improves liver function 128 and regulates the release of growth factors and antiapoptotic factors, which maintain the integrity of hepatocytes and promote their proliferation. 136 Current and future aims of HRT Estrogens regulate both reproductive and metabolic func tions, which have adapted to the reproductive cycle with fluctuating production of the metabolites relevant for energy storage or utilization. 26 Estradiol is the molecule most likely to be responsible for the beneficial effects of estrogens on metabolism, because it is the most potent and predominant form of estrogen during the fertile age, and its levels substantially decrease after menopause. However, the literature on levels of individual estrogen metabolites and their physiological effects is limited and often conflicting. Furthermore, we still do not under stand the exact consequences of either the termination of ovarian activity or the oscillation of metabolic functions. Experimental and clinical observations show that ovari ectomy disrupts the rhythm of ERα activation in the liver 26 and induces rapid disorganization of lipid metabolism characterized by accumulation of hepatic fat deposits. 26, 79 Decreased circulating estrogens and the lack of estrogen receptor oscillatory activity that occurs after menopause might trigger a derangement of energy metabolism in organs that are targets of estrogen action, such as adipose tissue, muscle and hypothalamus. Functional deteriora tion leading to the onset of specific pathologies (cancer, immune, neuropsychiatric, cardiovascular and cerebro vascular diseases) are also observed with desynchrony of the circadian rhythm, which is generated by clock genes and proteins that regulate sleep and wakefulness, body temperature, blood pressure, digestive secretion, immune responses and metabolism. [137] [138] [139] [140] [141] In analogy with such findings, the observed lack of efficacy of HRT with regard to menopauseassociated dysmetabolism might plausibly be caused by their inability to reinstate the oscillatory activity of ERα and ERβ in sexually mature individuals 21 and the consequent reciprocal control of genes regulating both fertility and energy metabolism.
The aim of all forms of HRT used to date has been to keep hormone levels constant. However, in some organs, cyclical modulation of ERα and ERβ signalling might be necessary to activate the expression of large numbers of genes whose products maintain energy homeostasis. For example, hepatic ERα becomes associated with distinct classes of promoters during different phases of the estrous cycle, 26 which might be necessary to poise ERα signalling for rapid selection of the transcriptome most appropri ate for the specific energy requirements of each stage of the reproductive cycle. Previous studies in our laboratory suggest that selective estrogen receptor modulators, either alone or in combination with natural hormones, might have a substantial effect on the relative phasing and inten sity of ERα and ERβ activity in target organs. 26, 142 These findings raise the possibility that the complex actions of ERα and ERβ in the whole organism might eventually be reproduced pharmacologically. However, currently a clear understanding of the pattern of ERα and ERβ activity that would have the most favourable effect on women's health during ageing is lacking. In the absence of such knowl edge, we believe that the analysis of the effects of existing forms of HRT on a single parameter (such as the period or amplitude of ERα or ERβ activity in different organs) is not sufficient to establish the superior ity of one treatment over another. Specific methodo logies and algorithms for the comparative analysis of multivariate parameters of synthetic ERα and ERβ ligand activity should also be developed. 143 Initial animal studies have shown that screening, based on the wholebody analysis of ERα and ERβ, by molecular imaging is a viable method. 143 This innovative technique might aid the development of novel HRT modalities better able to mimic estrogens' effects during the reproductive cycle.
Conclusions
This Review underlines the close link between energy metabolism and reproduction, to provide a compre hensive view of the role of estrogens in mammalian physiology. Given the association between energy pro duction and reproductive activity, a main aim of HRT should be restoration of the metabolic functions charac teristic of women still undergoing reproductive cycling. However, in postmenopausal women, current forms of HRT cannot reinstate the low morbidity from skeletal, cardio vascular and metabolic diseases typical in women of fertile age. Improved understanding of the exact physiological role of estrogens is, therefore, required to develop new types of HRT that can address metabolic as well as hormonal derangements.
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